A new lawsuit has been filed in New Jersey federal court by a woman who alleges that Invokana adverse effects caused her to sustain serious personal injuries.

Plaintiff Linda H. is an Indiana resident who was prescribed Invokana by her physician in order to treat her type-2 diabetes.

As a result of ingesting the drug, Linda asserts that she developed ketoacidosis from Invokana adverse effects.

Invokana belongs to a class of pharmaceutical medications known as sodium glucose co-transporter 2, or SGLT2, inhibitors.

These drugs work by inhibiting the reabsorption of glucose in the kidney and instead cause the glucose to be excreted via the urinary tract.

Because the kidney is directly targeted by Invokana and other drugs in its class, the organ undergoes additional stress induced by the use of the medication.

Invokana Adverse Effects Led to Hospitalization

As a result of the alleged adverse effects Laura developed from her alleged Invokana-induced ketoacidosis, she said she was hospitalized for multiple days.

“Plaintiff has endured pain and suffering, emotional distress, loss of enjoyment of life, and economic loss, including significant expenses for medical care and treatment which will continue in the future,” the Invokana adverse effects lawsuit states.

The lawsuit goes on to state that, “Defendants misrepresented that Invokana is safe and effective treatment for type 2 diabetes mellitus when in fact drug causes serious medical problems which require hospitalization and can lead to life-threatening complications, including but not limited to diabetic ketoacidosis and its sequelae, kidney failure and its sequelae, as well as serious cardiovascular problems.”

The Invokana adverse effects lawsuit states that Laura’s injuries were preventable and were the result of the drug manufacturers’ “failure and refusal to conduct proper safety studies, failure to properly assess and publicize alarming safety signals, suppression of information revealing serious and life-threatening risks, willful and wanton failure to provide adequate instructions, and willful misrepresentations concerning the nature and safety of Invokana.”

Laura alleges that the maker of Invokana purposely withheld information from the FDA, as well as misrepresented important information regarding the drug’s risks and benefits in communication with the FDA.

“These omissions and misrepresentations included failing to report instances of diabetic ketoacidosis to the FDA, failure to properly categorize adverse events of clinical trials, post-marketing trials, and obtained through its adverse event reporting system, and withholding of relevant information from pre-clinical and clinical trials.”

Her lawsuit states that physicians and consumers took the information provided by the manufacturers of Invokana at face value, but this led to unsafe outcomes. “Consumers of Invokana and their physicians relied on the Defendants’ false representations of her misled as to the drug’s safety, and as a result have suffered injuries including diabetic ketoacidosis, kidney failure, cardiovascular problems, and life-threatening competition thereof.”

Laura has brought forth several counts against the defendants including design defect, failure to warn, negligence, breach of express and implied warranties, gross negligence, fraudulent misrepresentation, negligent misrepresentation, fraudulent concealment, concert of action and punitive damages.

She is seeking a jury trial and is demanding judgment against the drug manufacturers for “compensatory, treble, and punitive damages together with interest; costs of suit, attorneys’ fees, and all such relief as the Court deems proper.”

The Invokana Adverse Effects Lawsuit is Case No. 3:16-cv-08907, in the U.S. District Court for the District of New Jersey.